“Cancer Prevention and Research Institute of Texas (CPRIT): Opportunities and Challenges”

Alfred G. Gilman, M.D., Ph.D.
Chief Scientific Officer, Cancer Prevention and Research Institute of Texas

Alfred Gilman, M.D., Ph.D.

Tuesday, December 7, 2010
5:45 p.m. – Networking Reception
6:30 p.m. – Presentation

The Cancer Prevention and Research Institute of Texas (CPRIT) is a new state agency, empowered by the Texas Legislature and a constitutional amendment, to invest $3 billion over ten years to enhance research and prevention activities toward alleviation of suffering and death from cancer.

During CPRIT’s first year of operation (FY2010), 111 awards totaling approximately $195,000,000 were made for research projects. Ten extremely promising and accomplished scientists have been recruited to Texas under these programs. While the majority of funds have gone to the academic health science centers, including The University of Texas M.D. Anderson Cancer Center, UT Southwestern Medical Center, and the Baylor College of Medicine, awards have also been made to general academic campuses and to companies.

A new CPRIT-funded initiative is a statewide clinical trials network (CTNeT). It is essential that this effort involve collaboration between the academic and community oncology practices in the state. Coupled with the clinical trials network will be a Biorepository, operated to standards set by the NCI-funded Cancer Genome Atlas Project by Richard Gibbs at the Human Genome Sequencing Center at The Baylor College of Medicine in Houston. Further, a Molecular Diagnostics Laboratory will be organized at Baylor by Arthur Beaudet. Within a few years, most cancers will be subjected to extraordinary diagnostic tests, including complete genome sequencing, to define the genetic alterations that cause the multiple subtypes of common cancers and to permit individualized therapy. These data will be coupled with detailed clinical information, including images, treatments, and outcomes.

This vision poses enormous questions about distributed clinical trials management systems, as well as means for acquisition, storage, analysis, integration, and dissemination of vast amounts of information. How will it be harmonized among different groups? How should the missing pieces be developed? How can an operation such as CTNeT proceed in the meantime? How can these needs be met in a timely and affordable fashion? Please join The Austin Forum and Dr. Alfred G. Gilman to learn more about CPRIT – its opportunities and challenges.


Dr. Gilman left UT Southwestern in 2009 to become the Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas (CPRIT). He is responsible for ensuring that grant monies fund the most meritorious attempts to discover more effective ways to prevent, diagnose, and treat cancer. In 1994, Dr. Gilman received the Nobel Prize in the category “Physiology or Medicine” for his discovery of G proteins and the role these proteins play in regulation of cell function. He has received other significant recognition for his work, including election to the U.S. National Academy of Sciences, the Albert Lasker Basic Medical Research Award, and several honorary degrees.